✦ LIBER ✦

Clinical Utility of Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor—1 Determination in Primary Breast Cancer Tissue for Individualized Therapy Concepts

✍ Scribed by Nadia Harbeck; Manfred Schmitt; Ronald E. Kates; Marion Kiechle; Iris Zemzoum; Fritz Jänicke; Christoph Thomssen

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Biological effects of inactivation of th

✍ P. Carmeliet; L. Schoonjans; L. Kieckens; J.M. Stassen; R. Bronson; D. Collen; R 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 290 KB

Physiological and pathological changes o

✍ Hyun Cheol Chung; Sun Young Rha; Joon Oh Park; Nae Choon Yoo; Joo Hang Kim; Jae 📂 Article 📅 1998 🏛 Springer US 🌐 English ⚖ 670 KB

Role of urokinase-type plasminogen activ

✍ E. Steiner; K. Pollow; D. Hasenclever; W. Schormann; M. Hermes; M. Schmidt; A. P 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 799 KB

Urokinase-Type Plasminogen Activator and

✍ Nadia Harbeck; Ronald E. Kates; Manfred Schmitt; Katja Gauger; Marion Kiechle; F 📂 Article 📅 2004 🏛 CIG Media Group, LP. 🌐 English ⚖ 118 KB

Prognostic value of urokinase-type plasm

✍ Schmitt, M.; Jänicke, F.; Thomssen, C.; Pache, L.; Bläser, J.; Oppelt, P.; Tsche 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 154 KB

Expression of plasminogen activator inhi

✍ Remedios Castelló; Jose M. Landete; Francisco España; Carlos Vázquez; Carlos Fus 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 1018 KB